We're learning from the U.S. proposals. Functionally, within Health Canada, we also get the benefit of a lot of the tools that have been constructed by the U.S., for example, the REMS—so the plans going out into market to follow vigilance. We do get those filed. We also get them filed from Europe. There's been a convention that we've been part of through the International Conference on Harmonization on pharmacovigilance for Health Canada. We've implemented much of that. The thing is to follow in with the regulatory proposals. That's what this would do in the orphan drug setting. It would put in an ability to require a plan to go out into the market and follow the safety issues as a part of your licence. So the company would be obligated by law to make sure that they are tracing out and actively looking for signals where we need to.
On May 2nd, 2013. See this statement in context.